

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

APREPITANT INJECTION OBTAINS DRUG REGISTRATION APPROVAL

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Aprepitant Injection (4.4ml:32mg) (the “**Product**”) developed by the Group has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China.

The Product is a submicron emulsion injection of a new-generation neurokinin-1 (NK-1) receptor antagonist, which can bind with high selectivity to NK-1 receptors in the brain and antagonise substance P to effectively prevent acute and delayed vomiting. The Product is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Compared to the traditional dosage form of aprepitant, the Product has a faster onset of action, can significantly improve patient compliance, and effectively reduce the incidence of allergic reactions during clinical use, providing a better medication option for the prevention of postoperative nausea and vomiting in adults.

The Aprepitant Injection (18ml:130mg) developed by the Group obtained drug registration approval in September 2024. It is primarily indicated for the prevention of nausea and vomiting associated with chemotherapy. The approval of the Product will further enhance the Group’s competitiveness in the antiemetic field.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 23 March 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.